LACTOSE (INDIA) LTD.
Latest filings
- NCLT approves amalgamation of Vitanosh Ingredients into Lactose India · Strategic Transactions
- Quarterly demat compliance certificate submitted to BSE · Compliance
- AGM results: All 6 resolutions passed with 100% approval · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products in Gujarat with a current production capacity of 10,000 metric tonnes per annum. FY26 revenue was Rs 163.29 crore, up 40.3% year-on-year, while net profit rose 17.4% to Rs 6.06 crore. EBITDA margin compressed from 14.6% in FY25 to 11.2% in FY26 as material costs rose faster than revenue. Raw materials are the largest cost, accounting for 53.6% of revenue in FY26, followed by other operating expenses at 22.4% and employee cost at 8.6%. The company is seeking NCLT and SEBI approval to amalgamate with Vitanosh Ingredients Private Limited, a related-party merger whose promoters are family members of the company's promoters, that would lift production capacity to 15,000 MT per annum. Working capital is funded through Rs 90 crore of bank facilities (long-term rating BBB-/Stable from CRISIL), including Rs 35 crore cash credit from Bank of Baroda, Rs 25 crore from YES Bank, and a Rs 30 crore term loan from Bank of Baroda.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from LACTOSE (INDIA) LTD.'s filed financials and exchange disclosures
What does LACTOSE (INDIA) LTD. do?
LACTOSE (INDIA) LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is LACTOSE (INDIA) LTD. profitable?
Yes. Over the trailing twelve months LACTOSE (INDIA) LTD. reported a net profit of ₹6.93 Cr on revenue of ₹171 Cr.
Does LACTOSE (INDIA) LTD. pay a dividend?
Not in the latest reported year — LACTOSE (INDIA) LTD.'s dividend payout for FY26 was nil.
Is LACTOSE (INDIA) LTD. debt-free?
No. It reported borrowings of ₹62 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹61 Cr after cash. Debt stands at 0.95× equity. That is higher than 92% of its 166 Pharmaceuticals peers.
Is LACTOSE (INDIA) LTD. expensive compared with its peers?
On trailing P/E, LACTOSE (INDIA) LTD. ranks 45 of 160 in Pharmaceuticals — cheaper than 72% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
How much does the LACTOSE (INDIA) LTD. share price move in a day?
On a typical session LACTOSE (INDIA) LTD. moves 1.81% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track LACTOSE (INDIA) LTD.'s announcements?
Every NSE and BSE filing by LACTOSE (INDIA) LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.